Strategy
Delivering on our Promise
Our highly experienced cancer drug development organization is committed to advancing voreloxin through clinical trials. Voreloxin is currently being evaluated as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer, in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly acute myeloid leukemia (AML) patients unlikely to benefit from standard induction chemotherapy, and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.
Our voreloxin development program has benefited from nonclinical, translational research providing us with an in-depth understanding of a compound's mechanism and potential activity. These insights ensure that voreloxin demonstrates a strong, differentiated pharmaceutical profile and informs clinical trial design, with a view to increase efficiencies and reduce risks.
